A complex growth story that moved significantly higher on its own merit. We first reccommended IMUC after it had been removed from the Russell 2000 for valuation reasons. From there at $2.15, it traded all the way to $4 in the last month.
This was for good reason. New information came out about their original ICT-107 trial. 8 of the 16 glioblastoma patients lived for a full five years, just plain miraculous.
It was very disappointing then, that the current trial reported results that were nowhere near as encouraging.
We have reviewed the released results and listened to the conference call, and along with our original research and the follow up data from the original trial, this is our summarized opinion:
This trial's data will continue to get better over time, like the original. Some patients will show a continued response, but this information will take years to play out, as with the original trial. I do not think that IMUC will have a product in the market for years, and I think that is a shame. I think that eventually IMUC will raise money and run a phase III trial in ICT-107.
We did not sell the IMUC shares we had before the news, and we have no plans to. But we think it will take a long time before IMUC recovers.